Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

S. I. Rennard, W. Anderson, R. ZuWallack, J. Broughton, W. Bailey, M. Friedman, M. Wisniewski, K. Rickard

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages. This study evaluated salmeterol, a β-agonist bronchodilator with a duration of action substantially longer than that of short-acting β-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. Four hundred and five patients with COPD received either salmeterol 42 μg twice daily, ipratropium bromide 36 μg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. Patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were randomized within each stratum. Bronchodilator response was measured over 12 h four times during the treatment period. Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance. Both active treatments were well tolerated. Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those "unresponsive" to albuterol. The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.

Original languageEnglish (US)
Pages (from-to)1087-1092
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume163
Issue number5
DOIs
StatePublished - Jan 1 2001

Fingerprint

Adrenergic Agonists
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Ipratropium
Albuterol
Placebos
Cholinergic Antagonists
Salmeterol Xinafoate
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. / Rennard, S. I.; Anderson, W.; ZuWallack, R.; Broughton, J.; Bailey, W.; Friedman, M.; Wisniewski, M.; Rickard, K.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 5, 01.01.2001, p. 1087-1092.

Research output: Contribution to journalArticle

Rennard, S. I. ; Anderson, W. ; ZuWallack, R. ; Broughton, J. ; Bailey, W. ; Friedman, M. ; Wisniewski, M. ; Rickard, K. / Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. In: American Journal of Respiratory and Critical Care Medicine. 2001 ; Vol. 163, No. 5. pp. 1087-1092.
@article{7a7b1b2fe71843bd950b084cdbe04da5,
title = "Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease",
abstract = "Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages. This study evaluated salmeterol, a β-agonist bronchodilator with a duration of action substantially longer than that of short-acting β-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. Four hundred and five patients with COPD received either salmeterol 42 μg twice daily, ipratropium bromide 36 μg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. Patients were stratified on the basis of bronchodilator response to albuterol (> 12{\%} and > 200-ml improvement) and were randomized within each stratum. Bronchodilator response was measured over 12 h four times during the treatment period. Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance. Both active treatments were well tolerated. Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those {"}unresponsive{"} to albuterol. The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.",
author = "Rennard, {S. I.} and W. Anderson and R. ZuWallack and J. Broughton and W. Bailey and M. Friedman and M. Wisniewski and K. Rickard",
year = "2001",
month = "1",
day = "1",
doi = "10.1164/ajrccm.163.5.9903053",
language = "English (US)",
volume = "163",
pages = "1087--1092",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

AU - Rennard, S. I.

AU - Anderson, W.

AU - ZuWallack, R.

AU - Broughton, J.

AU - Bailey, W.

AU - Friedman, M.

AU - Wisniewski, M.

AU - Rickard, K.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages. This study evaluated salmeterol, a β-agonist bronchodilator with a duration of action substantially longer than that of short-acting β-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. Four hundred and five patients with COPD received either salmeterol 42 μg twice daily, ipratropium bromide 36 μg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. Patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were randomized within each stratum. Bronchodilator response was measured over 12 h four times during the treatment period. Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance. Both active treatments were well tolerated. Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those "unresponsive" to albuterol. The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.

AB - Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages. This study evaluated salmeterol, a β-agonist bronchodilator with a duration of action substantially longer than that of short-acting β-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD. Four hundred and five patients with COPD received either salmeterol 42 μg twice daily, ipratropium bromide 36 μg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study. Patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were randomized within each stratum. Bronchodilator response was measured over 12 h four times during the treatment period. Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance. Both active treatments were well tolerated. Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those "unresponsive" to albuterol. The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.

UR - http://www.scopus.com/inward/record.url?scp=0035040553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035040553&partnerID=8YFLogxK

U2 - 10.1164/ajrccm.163.5.9903053

DO - 10.1164/ajrccm.163.5.9903053

M3 - Article

C2 - 11316640

AN - SCOPUS:0035040553

VL - 163

SP - 1087

EP - 1092

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -